Source: European Medicines Agency (EU) Revision Year: 2023 Publisher: AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Maviret 50 mg/20 mg coated granules in sachet.
Pharmaceutical Form |
---|
Coated granules. Pink and yellow granules. |
Each sachet contains 50 mg glecaprevir and 20 mg pibrentasvir.
Excipient with known effect: Each sachet of coated granules contains 26 mg of lactose (as monohydrate) and 4 mg propylene glycol.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Glecaprevir and Pibrentasvir |
Glecaprevir/Pibrentasvir is a fixed-dose combination of two pan-genotypic, direct-acting antiviral agents, glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor), targeting multiple steps in the HCV viral lifecycle. |
List of Excipients |
---|
Granule core: Copovidone Granule coating: Hypromellose (E464) |
Maviret coated granules are supplied in polyethylene terephthalate (PET)/aluminium/polyethylene film sachets in cartons. Each carton contains 28 sachets.
AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
EU/1/17/1213/003
Date of first authorisation: 26 July 2017
Date of latest renewal: 22 March 2022
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.